No pathway to BPC-157 approval through expedited review programs (Fast Track, Breakthrough Therapy) is currently listed in the FDA's public database
Jorsal A, Kistorp C, Holmager P et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
Even if we get to the point that medications alone can help people with obesity lose weight while preserving muscle, being in the normal weight range with a good muscle-to-fat ratio doesnt guarantee good health as much as we might wish it werent true, a better diet and more exercise might still be necessary
Experimental data indicate BPC-157 promotes angiogenesis and supports vascular integrity by activating VEGFR2Aktendothelial nitric oxide synthase (eNOS) signaling